1Department of Surgery, College of Medicine, Qadisiyah University, Iraq
2Department of Pathology, College of Medicine, Qadisiyah University, Iraq
*Corresponding Author: Shoroq Mohammed AL-Temimi, Department of Pathology, College of Medicine, Qadisiyah University, Iraq, Email: shoroqaltemimi@yahoo.com
Online published on 23 December, 2019.
MicroRNAs are a sequence of short (∼22nt), single-stranded RNA molecules that act as post-transcriptional controllers of gene expression. Circulating microRNAs as the potential minimally-invasive biomarkers for early detection and progression of prostate carcinoma. Therefore, the aim of the study was to find out the potential application of using circulating microRNA-205 to detect prostate cancer among patients with benign prostatic hyperplasia and find its correlation with age and stage of tumors.
Real-Time PCR was done to demonstrate the gene expression of microRNA-205 in serum sample of patients with prostate cancer, benign prostatic hyperplasia and control groups. The expression levels of microRNA-205 were calculated relative to messenger RNA of Glyceraldehyde 3-phosphate dehydrogenase and determined using the livak method.
microRNA-205 expression level in tissue samples was significantly down-regulated in prostate carcinoma in comparison to normal adjacent tissues and also the serum level was significantly down-regulated in prostate cancer cases in comparison to apparently healthy controls and benign prostatic hyperplasia.
Serum-microRNA-205 gene expression can serve as minimally-invasive biomarkers and standard screening tool for early detection of prostate cancer and for detection of higher stage from early stage of the tumor.
MicroRNA-205, RT-PCR, Livak method, Prostate cancer, Benign Prostatic Hyperplasia
